Metabolic syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 36: | Line 36: | ||
===Diabetes=== | ===Diabetes=== | ||
* Use of drugs that decrease [[insulin resistance]] e.g., [[metformin]]. Use of [[thiazolidinedione]]s is controversial and not FDA approved. | * Use of drugs that decrease [[insulin resistance]] e.g., [[metformin]] <ref name="pmid15838067">{{cite journal| author=Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S et al.| title=The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. | journal=Ann Intern Med | year= 2005 | volume= 142 | issue= 8 | pages= 611-9 | pmid=15838067 | doi= | pmc=PMC2505046 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15838067 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16262224 Review in: ACP J Club. 2005 Nov-Dec;143(3):67] </ref>. Use of [[thiazolidinedione]]s is controversial and not FDA approved. | ||
===Cardiovascular risk=== | ===Cardiovascular risk=== | ||
Revision as of 02:45, 29 September 2011
|
Metabolic syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Metabolic syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Metabolic syndrome medical therapy |
|
Risk calculators and risk factors for Metabolic syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
Metabolic syndrome is formed by a constellation of medical disorders that increases one's risk for cardiovascular disease and diabetes. It effects a large number of people in a clustered fashion. Management of metabolic syndrome involves dietary modifications, exercise and drug therapy for the complications (diabetes, stroke, angina, myocardial infarction) found associated with these conditions.
Treatment
- The first line treatment is change of lifestyle (i.e., caloric restriction, physical activity, weight loss). However, drug treatment is frequently required for complications that are seen with them.
Hypertension
- BP goal- 140/90 or 130/80 in diabetics (JNC 7 guidelines).
- Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) should be preferred over diuretics or beta-blockers in these patients [1].
Elevated low-density lipoprotein cholesterol (LDL-C)
- The goal is to get the LDL down to < 100 mg/dl.
- Statins are drug of choice.
- Statins are however contraindicated in pregnancy.
Decreased high-density lipoprotein cholesterol (HDL-C)
- Diet (decreased calorie intakes)
- Increased physical activity
- Niacin
- Cholesteryl ester transfer protein (CETP) inhibitors (torcetrapib) and (anacetrapib) are in trial stages and their benefits in increasing HDL levels are yet to be proved.
Elevated Triglyceride
- Fibric acid
- Niacin {however at higher doses (>1500 mg/d) it may exacerbate hyperglycemia}
- Addition of omega-3 fatty acids also produces beneficial effects.
Diabetes
- Use of drugs that decrease insulin resistance e.g., metformin [2]. Use of thiazolidinediones is controversial and not FDA approved.
Cardiovascular risk
- Aspirin therapy may be helpful in the primary prevention of cardiovascular complications
See also
References
- ↑ Suzuki T, Homma S (2007). "Treatment of hypertension and other cardiovascular risk factors in patients with metabolic syndrome". Med Clin North Am. 91 (6): 1211–23, x. doi:10.1016/j.mcna.2007.06.009. PMID 17964917.
- ↑ Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S; et al. (2005). "The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial". Ann Intern Med. 142 (8): 611–9. PMC 2505046. PMID 15838067. Review in: ACP J Club. 2005 Nov-Dec;143(3):67